Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature-Reference-Cited by-同舟云学术

Mono vs. combo regimens with novel beta-lactam/beta-lactamase inhibitor combinations for the treatment of infections due to carbapenemase-producing Enterobacterales: insights from the literature

Published:2021-02-03 Issue:3 Volume:49 Page:411-421
ISSN:0300-8126
Container-title:Infection
language:en
Short-container-title:Infection

Author:

Meini Simone^ORCID,Viaggi Bruno,Tascini Carlo

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s15010-021-01577-x.pdf

Reference44 articles.

1. Stewart A, Harris P, Henderson A, Paterson D. Treatment of infections by OXA-48-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62:e01195-e1218.

2. Crass RL, Pai MP. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors. Pharmacotherapy. 2019;39:182–95.

3. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-Lactam-β-Lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34:e00115-e120.

4. David 2019) David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. EuSCAPE Working Group; ESGEM Study Group, Feil EJ, Rossolini GM, Aanensen DM, Grundmann H. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4:1919–1929

5. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al; REIPI/ESGBIS/ INCREMENT Investigators. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017;17:726–34

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic antibacterial activity of ceftazidime–avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae;Scientific Reports;2024-07-30

2. Effect of achieving bone sterilisation on bone architecture and bone marrow, in an experimental rabbit model of osteomyelitis caused by carbapenemase-producing Enterobacterales;International Journal of Antimicrobial Agents;2023-12

3. In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM;Infection and Drug Resistance;2023-05

4. Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy;European Journal of Clinical Microbiology & Infectious Diseases;2023-02-20

5. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae;International Journal of Antimicrobial Agents;2023-01